Indivior PLC (LON:INDV)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | n/a |
| Revenue (ttm) | 905.57M |
| Net Income (ttm) | -47.99M |
| Shares Out | n/a |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | 12.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,726,430 |
| Average Volume | 704,436 |
| Open | 1,248.00 |
| Previous Close | 1,219.00 |
| Day's Range | 1,230.00 - 1,264.00 |
| 52-Week Range | 554.50 - 1,264.00 |
| Beta | 0.26 |
| RSI | 71.54 |
| Earnings Date | Jul 31, 2025 |
About Indivior
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]
Full Company ProfileNews
INDV Crosses Above Average Analyst Target
In recent trading, shares of Indivior PLC (Symbol: INDV) have crossed above the average analyst 12-month target price of $30.80, changing hands for $31.19/share. When a stock reaches the target an ana...
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with lowe...
Indivior PLC 2025 Q3 - Results - Earnings Call Presentation
INDV: Piper Sandler Raises Price Target Amidst Positive Outlook | INDV Stock News
INDV: Piper Sandler Raises Price Target Amidst Positive Outlook | INDV Stock News
Indivior (INDV) Maintained as 'Buy' by HC Wainwright & Co. ...
Indivior (INDV) Maintained as 'Buy' by HC Wainwright & Co., Price Target Raised to $35 | INDV Stock News
Indivior PLC (INDV) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Indivior PLC (INDV) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Restructuring
Indivior PLC (INDV) Q3 2025 Earnings Call Transcript
Here's Why Indivior Stock Soared 15% Today
Key PointsIndivior is already profitable and cash-generative, and is set to grow significantly in 2026.
Q3 2025 Indivior PLC Earnings Call Transcript
Q3 2025 Indivior PLC Earnings Call Transcript
Indivior Non-GAAP EPS of $0.72 beats by $0.31, revenue of $314M beats by $52.08M
Indivior PLC Q3 2025 Earnings: EPS Data Unavailable, Revenue Surpasses Estimates at $314 Million
Indivior PLC Q3 2025 Earnings: EPS Data Unavailable, Revenue Surpasses Estimates at $314 Million
Indivior PLC (INDV) Beats Q3 Earnings and Revenue Estimates
Indivior (INDV) delivered earnings and revenue surprises of +89.47% and +20.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Indivior Plc. Q3 Profit Increases, Beats Estimates
(RTTNews) - Indivior plc. (INDV.L) released a profit for its third quarter that Increased from last year and beat the Street estimates.
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOY Announces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support o...
Indivior PLC (INDV) Q3 2025: Everything You Need To Know Ahead Of Earnings
Indivior PLC (INDV) Q3 2025: Everything You Need To Know Ahead Of Earnings
Indivior to Participate in the Stifel 2025 Healthcare Conference
RICHMOND, Va. , Oct. 28, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Stifel 2025 Healthcare Conference: Stifel 2025 Healthcare Conference – New Yor...
Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th
RICHMOND, Va. , Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m.
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
Rapid induction with SUBLOCADE® showed higher treatment retention rates compared to standard induction, particularly among fentanyl-positive participants RICHMOND, Va. , Oct. 15, 2025 /PRNewswire/ -- ...
Indivior (INDV) Plans U.S. Domicile Shift with New Parent Company
Indivior (INDV) Plans U.S. Domicile Shift with New Parent Company
UK's Indivior to re-domicile to US after listing move
Indivior , said on Wednesday it plans to relocate its corporate domicile from the UK to the United States, establishing a new Delaware-based parent company, just months after the pharmaceutical firm m...
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation
RICHMOND, Va. , Oct. 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it intends to pursue a change in domicile from the U.K. to the U.S. and ...
Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Indivior explores alternatives for Opvee, announces restructuring details
Indivior to Participate in Upcoming Investor Events
RICHMOND, Va. , Aug. 20, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the following investor events: Morgan Stanley 23rd Annual Global Healthcare Confer...